ARTICLE | Emerging Company Profile
Seeking viral strongholds
How Agenovir is using CRISPR to eliminate HPV, other latent viral reservoirs
January 13, 2017 10:48 PM UTC
Agenovir Corp. is using CRISPR-based gene editing to eliminate latent viruses. Its lead program will test in vivo delivery of CRISPR-Cas9 components to treat persistent human papillomavirus infection.
Viruses that remain dormant within cells for years or decades after an acute infectious phase may recur or even drive pathologies while quiescent. Since they produce few proteins, they are nearly impossible to target and eradicate with conventional antiviral drugs or vaccines...